C3: Colorectal Cancer Coalition submitted comments at the December 16, 2008 Oncology Drug Advisory Committee (ODAC) hearing regarding the labels for Erbitux (cetuximab) and Vectibix (panitumumab), and whether or not they should include a mention of KRAS. The discussion during the meeting will have implications for future development of companion diagnostics.
- Patient Resources
- Get Involved!
- Fight Colorectal Cancer
- Fight Colorectal Cancer Position Statements
- C3 Comments on KRAS Testing to FDA ODAC Committee, 12/16/2008